%0 Journal Article
%T Therapeutic perspectives on PDE4B inhibition in adipose tissue dysfunction and chronic liver injury.
%A Staller DW
%A Bennett RG
%A Mahato RI
%J Expert Opin Ther Targets
%V 28
%N 7
%D 2024 Jul 19
%M 38878273
%F 6.797
%R 10.1080/14728222.2024.2369590
%X <B>UNASSIGNED: </B>Chronic liver disease (CLD) is a complex disease associated with profound dysfunction. Despite an incredible burden, the first and only pharmacotherapy for metabolic-associated steatohepatitis was only approved in March of this year, indicating a gap in the translation of preclinical studies. There is a body of preclinical work on the application of phosphodiesterase 4 inhibitors in CLD, none of these molecules have been successfully translated into clinical use.<BR><B>UNASSIGNED: </B>To design therapies to combat CLD, it is essential to consider the dysregulation of other tissues that contribute to its development and progression. As such, proper therapies must combat this throughout the body rather than focusing only on the liver. To detail this, literature characterizing the pathogenesis of CLD was pulled from PubMed, with a particular focus placed on the role of PDE4 in inflammation and metabolism. Then, the focus is shifted to detailing the available information on existing PDE4 inhibitors.<BR><B>UNASSIGNED: </B>This review gives a brief overview of some of the pathologies of organ systems that are distinct from the liver but contribute to disease progression. The demonstrated efficacy of PDE4 inhibitors in other human inflammatory diseases should earn them further examination for the treatment of CLD.